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Abstract. 
 
v-E10, a caspase recruitment domain
(CARD)-containing gene product of equine herpesvi-
rus 2, is the viral homologue of the bcl-10 protein whose
gene was found to be translocated in mucosa-associated
lymphoid tissue (MALT) lymphomas. v-E10 efficiently
 
activates the c-jun NH
 
2
 
-terminal kinase (JNK), p38 stress
 
kinase, and the nuclear factor (NF)-
 
k
 
B transcriptional
pathway and interacts with its cellular homologue, bcl-10,
via a CARD-mediated interaction. Here we demonstrate
that v-E10 contains a COOH-terminal geranylgeranyla-
tion consensus site which is responsible for its plasma
membrane localization. Expression of v-E10 induces hy-
perphosphorylation and redistribution of bcl-10 from
the cytoplasm to the plasma membrane, a process which
 
is dependent on the intactness of the v-E10 CARD mo-
tif. Both membrane localization and a functional CARD
 
motif are important for v-E10–mediated NF-
 
k
 
B induc-
tion, but not for JNK activation, which instead requires
a functional v-E10 binding site for tumor necrosis factor
 
receptor–associated factor (TRAF)6. Moreover, v-E10–
 
induced NF-
 
k
 
B activation is inhibited by a dominant
negative version of the bcl-10 binding protein TRAF1,
suggesting that v-E10–induced membrane recruitment
of cellular bcl-10 induces constitutive TRAF-mediated
NF-
 
k
 
B activation.
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Introduction
 
Members of the 
 
g
 
-herpesvirus family are characterized by
the ability to establish latent infections in lymphoid cells
and some of the primate 
 
g
 
-herpesviruses, such as Epstein-
Barr virus (EBV)
 
1
 
 and Kaposi’s sarcoma–associated hu-
man herpesvirus-8, are closely associated with abnormal
cell proliferation and cancer (for review see Damania et
 
al., 2000). Equine herpesvirus 
 
(
 
EHV)-2 is a slow grow-
ing lymphotropic 
 
g
 
-herpesvirus widely distributed in the
equine population (Telford et al., 1995), but its precise
role as a pathogen remains largely uncharacterized. The
virus has been reported to induce chronic pharingitis as-
sociated with lymphoid proliferation in infected horses
(Blakeslee et al., 1975). The persistence of the virus in in-
fected lymphocytes suggests that it has evolved strategies
to counteract the proapoptotic and growth-arresting pro-
cesses naturally occurring in the infected host cell.
Many 
 
g
 
-herpesviruses encode proteins (called viral
FLIPs) which inhibit induction of apoptosis through cas-
pase-8–dependent death receptors (for review see Tschopp
et al., 1998). Some 
 
g
 
-herpesviruses also encode membrane
proteins which actively induce proliferation of the infected
cells by activation of the nuclear factor (NF)-
 
k
 
B transcrip-
tional pathway (for review see Damania et al., 2000). The
 
tumor necrosis factor receptor–associated factor
 
 
 
(TRAF)
family of adapter proteins, which are important mediators
of cellular stress responses triggering the NF-
 
k
 
B and c-jun
NH
 
2
 
-terminal kinase (JNK) transcriptional pathways (for
review see Arch et al., 1998), play an essential role in this
activation. Indeed, the transforming activity of the EBV la-
tent membrane protein (LMP)1 is dependent, at least in
part, on the TRAF-mediated activation of the NF-
 
k
 
B path-
way, which induces the expression of antiapoptotic genes
such as bcl-2 and A20 (Henderson et al., 1991; Laherty et
al., 1992; Opipari et al., 1992). The herpesvirus Saimiri
transforming protein was also shown to activate NF-
 
k
 
B
through interaction with TRAFs (Lee et al., 1999).
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We have shown previously that the EHV-2 protein
E10 activates the NF-
 
k
 
B transcriptional pathway as well
as JNK and p38 stress kinases (Thome et al., 1999).
v-E10 binds to TRAF3 and TRAF6, whereas its cellular
homologue bcl-10 binds TRAF1, 2, and 5 (Thome et al.,
1999; Yoneda et al., 2000). v-E10 and bcl-10 contain a
highly homologous NH
 
2
 
-terminal caspase recruitment
domain (CARD) motif which allows for both homo- and
heterodimerization of the two proteins (Koseki et al.,
1999; Srinivasula et al., 1999; Thome et al., 1999). How-
ever, the two proteins differ in their COOH-terminal ex-
tensions. v-E10 contains a glycine-rich extension of 
 
z
 
200
amino acids, which shares very little sequence homology
with the shorter, serine/threonine-rich COOH terminus
of bcl-10 (Srinivasula et al., 1999; Thome et al., 1999),
suggesting that the two related proteins may target the
same biological pathway but with a different physiologi-
cal outcome.
The in vivo function of bcl-10 is still poorly defined. Vari-
ous reports have suggested a role for bcl-10 in induction of
apoptosis and NF-
 
k
 
B activation (Costanzo et al., 1999; Ko-
seki et al., 1999; Srinivasula et al., 1999; Thome et al., 1999;
Yan et al., 1999; Yoneda et al., 2000). A potential tumor-
suppressing function of bcl-10 has been postulated based on
genetic studies in which bcl-10 cDNA mutation and/or
abnormal expression of bcl-10 RNA has been correlated
with the formation of mucosa-associated lymphoid tissue
(MALT) B cell lymphomas and various other types of tu-
mors (Willis et al., 1999; Zhang et al., 1999). However, oth-
ers have reported a naturally occurring high degree of 
 
BCL-
10
 
 gene polymorphism which may be unrelated to tumor
formation (Apostolou et al., 1999; Fakruddin et al., 1999).
In this study, we have investigated the subcellular dis-
tribution of v-E10 and of its cellular homologue, bcl-10,
in the context of the induction of the JNK and NF-
 
k
 
B
transcriptional pathways. We find that v-E10 constitu-
tively associates with the plasma membrane and induces
hyperphosphorylation and partial redistribution of cyto-
plasmic bcl-10 to the membrane. Moreover, both mem-
brane localization and an intact CARD motif of v-E10
are important for the activation of the NF-
 
kB
 
, but not for
activation of the JNK pathway, which instead requires
v-E10 binding to TRAF6. These results provide new in-
sights into the molecular mechanism underlying v-E10
and bcl-10 function.
 
Materials and Methods
 
Expression Vectors
 
Expression vectors for v-E10 and bcl-10 with an NH
 
2
 
-terminal FLAG, or
vesicular stomatitis virus (VSV), tag and for dominant negative TRAF1
have been described previously (Thome et al., 1999; Irmler et al., 2000). A
deletion construct of v-E10 lacking the two COOH-terminal cysteine resi-
dues, cysteine 310 and 311 (v-E10
 
D
 
CC), point mutants of v-E10 where ei-
ther one of both cysteine residues was replaced by an alanine residue
(v-E10-CA and v-E10-AC); the CARD-mutant (L49R); and the TRAF6-
binding mutant (P
 
278
 
QE
 
fi
 
GQA) were obtained by amplification on cloned
full length wild-type v-E10 cDNA using standard PCR conditions and Pwo
polymerase (Boehringer). Amplified products were sequenced in both di-
rections and subcloned into expression vectors derived from pCR-3 to yield
expression constructs with an NH
 
2
 
-terminal FLAG or VSV tag. The
TRAF6 expression vector was a gift of V. Dixit (Genentech, San Francisco,
CA) and reporter plasmids NF-
 
k
 
BLuc and FLAG-JNK were gifts of V.
Jongeneel and C. Widmann (University of Lausanne), respectively.
 
Cell Lines and Culture Conditions
 
293T, HeLa, and NIH3T3 cells were grown in DME and Jurkat cells were
grown in RPMI 1640 medium, both supplemented with 10% heat-inacti-
vated FCS and penicillin/streptomycin (100 
 
m
 
g/ml of each).
 
Transient Cell Transfection, Immunoprecipitation, 
JNK, and NF-
 
k
 
B Activation Assays
 
These techniques were performed essentially as described previously
(Bodmer et al., 1997; Thome et al., 1999). Antibodies used for Western
blotting include anti-FLAG M2 and anti-VSV P5D4 monoclonal antibod-
ies (Sigma-Aldrich), rabbit anti-TRAF6 (H-274; Santa Cruz Biotechnol-
ogy, Inc.), and an antibody specifically detecting the activated (phosphor-
ylated) form of JNK (Promega).
Cellular (endogenous) bcl-10 was detected using an affinity-purified
polyclonal rabbit antibody (AL114) directed against a peptide encompass-
ing 24 NH
 
2
 
-terminal amino acids (SLTEEDLTEVKKDALENYRVL-
CEK) of murine bcl-10, synthesized using the multiple antigen technology
(Francis et al., 1991).
 
Generation of v-E10–expressing Jurkat and
NIH3T3 Clones
 
For generation of stable v-E10–expressing Jurkat clones, an NH
 
2
 
-termi-
nally FLAG-tagged v-E10 construct was subloned into an expression vec-
tor with IPTG-inducible promoter (LacSwitch inducible mammalian ex-
pression system; Stratagene). 8 
 
3
 
 10
 
6
 
 exponentially grown Jurkat cells were
transfected with 20 
 
m
 
g of v-E10 vector or empty vector by electroporation
at 250 kV and 960 
 
m
 
F and stable clones were selected in RPMI complete
medium with 300 
 
m
 
g/ml of hygromycin B (Calbiochem). For analysis of
v-E10 isoprenylation, Jurkat cells were treated for 48 h with 10 mM IPTG
and the indicated concentrations of lovastatin (Calbiochem) previously
converted to the open acid form as described (Liu et al., 1999).
For generation of stable v-E10–expressing NIH3T3 clones, an NH
 
2
 
-termi-
nally FLAG-tagged v-E10 construct in pCR-3 or an empty vector was trans-
fected into NIH3T3 cells using Effectene transfection reagent (QIAGEN)
according to the manufacturer’s instructions, and stable clones were selected
in DME complete medium with 1 
 
m
 
g/ml of G418 (GIBCO BRL).
 
Protein Dephosphorylation
 
Transfected 293T cells from a 5.5-cm dish were lysed in 1% NP-40 buffer
containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and
0.25 
 
m
 
g/ml Pefabloc
 
® 
 
SC (Serva) on ice. Aliquots (20 
 
m
 
g) of postnuclear
lysates were incubated with lambda protein phosphatase (New England
Biolabs, Inc.) in buffer supplied by the manufacturer for 1 h at 30
 
8
 
C.
 
Cellular Fractionation
 
293T cells (
 
z
 
5 
 
3
 
 10
 
5
 
) from a 5.5-cm dish were harvested and washed twice
with cold PBS, and cell pellets were resuspended in 100 
 
m
 
l of ice-cold lysis
buffer (20 mM Tris-HCl, pH 7.4, 10 mM EDTA, 5 mM EGTA, 0.1%
 
b
 
-mercaptoethanol, 1 mM Na
 
3
 
VO
 
4
 
, and protease inhibitors [100 ng/ml
benzamidine, Sigma-Aldrich; 10 ng/ml antipain and 2.5 ng/ml leupeptin,
Boehringer]) for 30 min on ice. Lysates were homogenized by 50 strokes
through a syringe with a 25G5/8 needle (0.5 
 
3
 
 16 mm) and centrifuged at
1,500 
 
g
 
 for 5 min to remove nuclei and cellular debris. Postnuclear lysates
were centrifuged at 100,000 
 
g
 
 for 1 h to yield the cytosolic supernatant and
the membrane pellet which were boiled in reducing SDS-PAGE sample
buffer for subsequent SDS-PAGE and Western blot analysis.
 
Triton X-114 Extraction
 
Cells (
 
z
 
10
 
6
 
) were harvested and submitted twice to Triton X-114 extrac-
tion (Bordier, 1981). Proteins of the aqueous and diluted detergent phases
were precipitated by the addition of MeOH/CHCl
 
3
 
 (1:4, vol/vol) and the
resulting protein pellet was dried, resuspended in reduced SDS-PAGE
sample buffer, sonicated, and boiled before loading for SDS-PAGE and
Western blotting.
 
Immunostaining and Confocal Laser
Scanning Microscopy
 
HeLa cells of 10–20% confluency were transfected on 20-mm glass cover-
slips by the calcium phosphate/BES method (Ausubel et al., 1999). 30 h
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after onset of transfection, cells on coverslips were washed twice with cold
PBS, fixed for 12 min in 4% paraformaldehyde at room temperature,
washed again, and permeabilized in PBS with 0.1% saponine (PBSS)
overnight at 4
 
8
 
C. Coverslips were blocked for 30 min at room temperature
with 5% milk in PBSS (PBSSM), stained with anti-VSV (1:50,000; Sigma-
Aldrich) or anti-FLAG (0.2 
 
m
 
g/ml; Zymed Laboratories) in PBSSM for
1 h at room temperature, washed three times with PBSS, and stained with
Cy5-labeled (Jackson ImmunoResearch Laboratories), Alexa-488–
labeled (Molecular Probes) secondary anti–mouse, or anti–rabbit anti-
body (1:100 in PBSSM) for 1 h in the dark. Finally, coverslips were
washed three times with PBS and mounted with FluorSave reagent (Cal-
biochem). Confocal microscopy was performed on an Axiovert 100 micro-
 
scope (laser scanning microscope model 510; ZEISS) with a 63
 
3
 
 oil objec-
tive. To detect the Cy5 fluorochrome, a helium laser was filtered at 633
nm; an argon laser at 488 nm was used to detect the Alexa fluorochrome.
Standardized conditions for the pinhole size, gain, and offset (brightness
and contrast) were used for image capture. Each image was the average of
16 scans. Digital images were prepared using Adobe Photoshop
 
®
 
.
 
Results
 
HeLa cells were transfected with an expression vector en-
coding FLAG-tagged v-E10 and the cellular distribution
of the transfected protein was analyzed by confocal laser
scanning microscopy. v-E10 was found exclusively local-
ized at the plasma membrane (Fig. 1 A). This subcellular
localization of v-E10 was corroborated biochemically by
Triton X-114 extraction (Fig. 1, B–D). v-E10 from tran-
siently transfected 293T and HeLa cells was found to par-
tition exclusively to the detergent-soluble membrane frac-
tion (Figs. 1 D and 2 A). Similar results were obtained
using stable clones of Jurkat and NIH3T3 cells expressing
v-E10 (Fig. 1, B and C).
v-E10 does not contain a putative transmembrane seg-
ment and must therefore be targeted to the plasma mem-
brane in some other manner. Covalent lipid modifications,
such as myristylation, palmitoylation, farnesylation, or
geranylgeranylation, can mediate membrane targeting of
proteins that lack a transmembrane domain (Casey and
Seabra, 1996; Resh, 1999). Indeed, the amino acid se-
quence of v-E10 terminates in two cysteine residues and
thus contains a cognate consensus site for geranylgeran-
ylation by geranylgeranyltransferase II (rab geranylge-
ranyltransferase), which transfers geranylgeranyl to proteins
terminating in CC, CXC, or CCXX (Seabra et al., 1992;
Glomset and Farnsworth, 1994). To investigate whether
the two COOH-terminal cysteine residues of v-E10 are
implicated in its membrane localization, we generated mu-
tants of v-E10 lacking both cysteine residues (v-E10
 
D
 
CC)
or in which either one of the two cysteine residues was re-
placed by an alanine residue (v-E10-CA and v-E10-AC,
respectively). Biochemical fractionation and confocal laser
scanning showed that v-E10 lacking both COOH-terminal
cysteine residues was localized in the cytoplasm and no
longer detectable in the membrane fraction (Fig. 2, A and
B). The subcellular distribution of the mutants v-E10-CA
and v-E10-AC was similar to the one observed for the de-
letion mutant, indicating that both Cys residues are re-
quired for plasma membrane targeting of v-E10 (Fig. 2 B).
The 3-hydroxymethylglutaryl-coenzyme A reductase in-
hibitor lovastatin inhibits isoprenylation, e.g., farnesyla-
tion and geranylgeranylation, by decreasing cellular pools
of farnesylpyrophosphate and geranylgeranylpyrophos-
phate, respectively. Pretreatment of stably v-E10–express-
ing Jurkat cells with lovastatin significantly reduced the
membrane localization of v-E10, but not of the unrelated
transmembrane protein Fas, whereas it did not affect the
overall expression levels of v-E10 (Fig. 2, C and D).
v-E10 associates with bcl-10 both in two-hybrid assays
and in coimmunoprecipitation experiments (Costanzo et
al., 1999; Koseki et al., 1999; Srinivasula et al., 1999;
Thome et al., 1999). This association requires an intact
CARD region of v-E10 since a v-E10 CARD point muta-
tion (L49R) homologous to a mutation previously demon-
strated to be important for CARD–CARD interaction in
Figure 1. v-E10 is localized at the plasma membrane. (A) HeLa
cells were cotransfected with expression plasmids for GFP and
VSV-tagged v-E10 and cells were stained using anti-VSV and
Cy5-labeled secondary antibody. Protein expression was ana-
lyzed by confocal laser scanning microscopy at 488 nm (green
staining of GFP) and 633 nm (red staining of VSV-tagged v-E10).
(B) Clones of Jurkat cells expressing FLAG-tagged v-E10 were
analyzed by Triton X-114 extraction, SDS-PAGE, and anti-
FLAG Western blot for repartition of v-E10 protein into cyto-
plasmic (c) and membrane (m) fractions. (C) Mock-transfected
and v-E10–expressing stable NIH clones were analyzed as in B.
(D) 293T cells were transfected with mock or v-E10 expression
vectors and the subcellular localization of v-E10 was analyzed as
in B. Bar, 10 mm.
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bcl-10 (Koseki et al., 1999; Srinivasula et al., 1999; Yan et
al., 1999) abolished the interaction (Fig. 3 A). Moreover,
v-E10 also binds to TRAF6 (Thome et al., 1999) and mu-
tation of a PQE consensus binding site (P
 
278
 
QE
 
fi
 
GQA)
located within the COOH-terminal part of v-E10 abol-
ishes the interaction in 293T cells (Fig. 3 B).
We took advantage of the mutants described above and
next analyzed whether membrane targeting of v-E10 or an
intact CARD motif or TRAF6 binding site were required
for previously described v-E10 effector functions, namely
activation of the JNK and NF-
 
k
 
B transcriptional pathways.
To this purpose, 293T cells were transfected with expression
constructs for wild-type or mutant v-E10, and cells were as-
sayed for JNK and NF-
 
k
 
B activation by cotransfection with
suitable reporter plasmids (Fig. 3, C and D). Mutation of
the COOH-terminal membrane-targeting motif of v-E10
 
did not appear to interfere with JNK activation, whereas
the TRAF6-binding mutant was greatly impaired in its ca-
pacity to activate JNK (Fig. 3 C). Mutation of the CARD
motif completely abolished NF-
 
k
 
B induction by v-E10,
whereas mutation of the COOH-terminal Cys-residues had
a partial effect on NF-
 
k
 
B activation (Fig. 3 D and data not
shown). Indeed, in three independent experiments done in
two different cell lines (293T and HeLa) and using variable
plasmid concentrations, the mean values of NF-
 
k
 
B induc-
tion by the v-E10 geranylgeranylation mutants were re-
duced compared with the wild-type v-E10 construct: to 47%
of wild-type levels (
 
P 
 
,
 
 0.005) for the v-E10
 
D
 
CC mutant, to
52% (
 
P 
 
, 
 
0.0004) for the v-E10-CA mutant, and to 42%
(
 
P 
 
, 
 
0.03) for the v-E10-AC mutant. Therefore, we conclude
that the geranylgeranylation mutants show a statistically
significant (approximately twofold) reduction in NF-
 
k
 
B ac-
Figure 2. v-E10 is targeted to the plasma mem-
brane via an isoprenylated COOH-terminal
Cys–Cys motif. (A) HeLa cells were transfected
with expression vectors for wild-type v-E10 (wt)
or v-E10 lacking the two COOH-terminal cys-
teine residues (v-E10DCC), and the subcellular
localization of both proteins was analyzed by
Triton X-114 extraction as described in the leg-
end to Fig. 1 B. (B) HeLa cells were transfected
as in A and the subcellular distribution of wild-
type v-E10 and its mutants v-E10DCC, v-E10-
CA, and v-E10-AC was analyzed by confocal
staining using anti-VSV– and Cy5-labeled sec-
ondary antibody. (C) Jurkat cells expressing
FLAG-tagged v-E10 or the parental clone (wt)
were treated for 60 h with the indicated concen-
trations of lovastatin, and membrane proteins
were analyzed by Triton X-114 extraction, SDS-
PAGE, and Western blotting with the indicated
primary antibodies. (D) Jurkat cells expressing
FLAG-tagged v-E10 or the parental clone (wt)
were treated for 60 h with the indicated concen-
trations of lovastatin, and total cellular extracts
or Triton X-114–extracted membrane proteins
were analyzed by SDS-PAGE and anti-FLAG
Western blotting. Bars, 10 mm.
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tivation. Mutation of the TRAF6 binding site, on the other
hand, did not affect NF-
 
k
 
B activation (Fig. 3 D).
In summary, these results show that membrane recruit-
ment and an intact CARD motif of v-E10 are important
for induction of the NF-
 
k
 
B pathway, whereas JNK activa-
tion appears to be mediated by the interaction of v-E10
with TRAF6.
In addition, we found that a dominant negative form of
the adaptor molecule TRAF1, which has been shown pre-
viously to bind to bcl-10, but not to v-E10 (Thome et al.,
1999), was able to inhibit v-E10–induced NF-
 
k
 
B activation
(Fig. 3 E), suggesting that NF-
 
k
 
B activation by v-E10 is
mediated by its interaction with bcl-10.
This led us to investigate whether the subcellular dis-
tribution of bcl-10 was altered in the presence of v-E10.
Bcl-10 has been reported to be localized in the cyto-
plasm in filamentous stress fiber–like structures (Yan et
al., 1999; Guiet and Vito, 2000). However, in our hands
Figure 3. Membrane target-
ing and an intact CARD mo-
tif of v-E10 are required for
the activation of NF-kB,
whereas TRAF6-binding me-
diates JNK activation. (A)
Association of v-E10 and bcl-
10 requires an intact CARD
domain. 293T cells were
cotransfected with expres-
sion vectors for FLAG-
tagged wild-type v-E10 or its
CARD mutant, v-E10 L49R,
and VSV-tagged wild-type
bcl-10 and anti-FLAG immu-
noprecipitates were ana-
lyzed for the presence of bcl-
10 by anti-VSV Western
blotting. The lower panels
show the expression levels of
the FLAG- and VSV-tagged
proteins in the cellular ex-
tracts. (B) v-E10 binds
TRAF6 via a PQE binding
motif. 293T cells were
cotransfected with expres-
sion vectors for FLAG-
tagged wild-type v-E10 or its
TRAF6 binding mutant
(P278QE fi GQA) and hu-
man full length TRAF6, and
anti-TRAF6 immunoprecipi-
tates were analyzed for the
presence of v-E10 by anti-
FLAG Western blotting. The
lower panels show the ex-
pression levels of FLAG–
v-E10 and TRAF6 in the cel-
lular extracts. (C) 293T cells
(2 3 105) were transfected
with 2 mg of a JNK expres-
sion vector together with 5
mg (11) or 1 mg (1) of ex-
pression vectors for v-E10,
its COOH-terminal mutants
v-E10DCC, v-E10-CA, and
v-E10-AC, and its TRAF6-
binding mutant (T6-mut). 24 h after transfection, the presence of FLAG-tagged JNK and of its activated form was assessed by Western
blotting using anti-FLAG M2 and an antibody directed against the activated phosphorylated form of JNK (P-JNK), respectively. Ex-
pression levels of the various v-E10 mutants were assessed by Western blotting of total cell extracts using anti-VSV. (D) HeLa cells (2 3
105) were cotransfected with 2 mg of an NF-kB luciferase reporter plasmid, 0.5 mg of b-galactosidase expression vector, and 10, 1, 0.1, or
0.01 mg of the indicated v-E10 constructs. The total amount of plasmid was normalized with empty vector. Luciferase activities were de-
termined 24 h after transfection and normalized on the basis of b-galactosidase values. Data shown are mean values 6 standard devia-
tions from one representative out of three independent experiments, each done in triplicate. (E) v-E10–induced NF-kB activation is in-
hibited by dominant negative (DN) TRAF1. HeLa cells (2 3 105) were transfected with 100 ng (1) of a v-E10 expression vector,
together with the indicated amounts (in mg) of a dominant negative TRAF1 construct, and luciferase activities were determined as in B.
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bcl-10 shows a granular staining pattern in the cyto-
plasm of transfected HeLa cells (Fig. 4 A). Filamentous
structures were observed only when considerably higher
concentrations of the bcl-10 expression vector were
used (data not shown). In cells cotransfected with v-E10,
a significant portion of bcl-10 was now redistributed to
the plasma membrane (Fig. 4 A). Coimmunostaining of
HeLa cells transfected with both v-E10 and bcl-10 ex-
pression constructs and analysis by confocal laser scan-
ning microscopy revealed a clear colocalization of the
two proteins at the plasma membrane in cotransfected
cells (Fig. 4 B). Consistent with this observation, cellu-
lar (endogenous) bcl-10 was found to partially redistrib-
ute to the membrane fraction in v-E10–transfected
HeLa cells (Fig. 4 D).
Bcl-10 has been suggested to be posttranslationally
modified by phosphorylation (Koseki et al., 1999; Sriniva-
sula et al., 1999; Thome et al., 1999; Yoneda et al., 2000).
Coexpression of v-E10 induces the formation of hyper-
phosphorylated forms of bcl-10, as shown by treatment of
the lysates with l-phosphatase (Fig. 4 C). Interestingly, the
membrane-targeted population of cellular bcl-10 was
clearly enriched in these hyperphosphorylated forms (Fig.
4 D). This suggests that v-E10–induced recruitment of bcl-
10 to the membrane is required for its phosphorylation.
Discussion
In this report, we have studied the molecular function of
v-E10 and of its cellular homologue, bcl-10, in the context
of their subcellular distribution. v-E10 was found to local-
ize to the plasma membrane via a COOH-terminal Cys–
Cys motif, which represents a consensus site for geranyl-
geranylation by geranylgeranyltransferase II (Farnsworth
et al., 1994). Mutation of the Cys–Cys consensus site or
pretreatment of the cells with lovastatin significantly and
specifically reduced the membrane localization of v-E10.
It is reasonable to assume that both cysteine residues of
v-E10 are geranylgeranylated, since in Rab proteins termi-
nating in Cys–Cys, both cysteines were found to be geran-
ylgeranylated (Peter et al., 1992; Wei et al., 1992; Farns-
worth et al., 1994).
Ectopic expression of v-E10 induced the membrane re-
cruitment and concurrent phosphorylation of endogenous
bcl-10. Currently, very little is known about the in vivo
function of bcl-10. The BCL-10 gene was originally identi-
fied based on its chromosomal location close to the t(1;
14)(p22; q32) translocation breakpoint associated with
some aggressive cases of MALT B cell lymphomas (Willis
et al., 1999; Zhang et al., 1999). (Over)expression of mu-
tated and/or truncated forms of bcl-10 mRNA has been
suggested to be causally related to the development of
Figure 4. v-E10 induces
hyperphosphorylation and
plasma membrane recruit-
ment of bcl-10. (A) Bcl-10 is
localized in the cytoplasm of
HeLa cells. HeLa cells were
transfected with 0.5 mg of an
expression vector for FLAG-
tagged bcl-10 together with
4.5 mg of mock vector; the
subcellular distribution of
the transfected bcl-10 protein
was analyzed by confocal
staining using rabbit anti-
FLAG antibody and Alexa-
488–labeled anti–rabbit sec-
ondary antibody. (B) v-E10
and bcl-10 colocalize at the
plasma membrane. HeLa
cells were cotransfected with
expression vectors for
FLAG-tagged bcl-10 (0.5
mg), VSV-tagged v-E10 (2
mg), and mock vector
(2.5 mg); the subcellular dis-
tribution of the transfected
proteins was analyzed by
confocal staining using rabbit
anti-FLAG and mouse anti-
VSV antibody followed by
Alexa-488–labeled anti–rabbit and Cy5-labeled anti–mouse secondary antibody. (C) v-E10 induces hyperphosphorylation of bcl-10.
HeLa cells were cotransfected with expression vectors for FLAG-tagged bcl-10 (1 mg) and VSV-tagged v-E10 (3 mg), and cell extracts
of transfected cells were incubated for 1 h in the presence or absence of l-phosphatase, as indicated. Cell lysates were analyzed by
Western blotting using affinity-purified anti–bcl-10 antibody (AL114). Arrowheads indicate the migration position of the nonphosphor-
ylated and the hyperphosphorylated forms of bcl-10. (D) v-E10 recruits hyperphosphorylated bcl-10 to the plasma membrane. HeLa
cells were transfected with 3 mg of an expression vector for FLAG-tagged v-E10 and the subcellular distribution of the transfected v-E10
and the endogenous bcl-10 proteins was analyzed by cellular fractionation and Western blotting using anti-FLAG and anti–bcl-10
(AL114) antibodies, respectively. Bars, 10 mm.
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MALT lymphomas and various other tumors lacking the
t(1;14)(p22; q32) translocation (Willis et al., 1999; Zhang
et al., 1999). However, other studies have subsequently
identified similar sequence variations with comparable
frequency in normal tissues, suggesting that the observed
bcl-10 mutations represent a naturally occurring genetic
polymorphism rather than tumor-specific mutations (Apos-
tolou et al., 1999; Fakruddin et al., 1999).
Interestingly, a proapoptotic and antiproliferative (thus
potentially NF-kB inhibitory) role of bcl-10 was suggested
by a recent study of bcl-10 transgenic mice (Yoneda et al.,
2000). These mice showed lymphoid depletion and atro-
phy of the thymus and spleen, which could be correlated
with accelerated apoptosis of B and T cells, suggesting that
an increase in the cellular bcl-10 expression levels could
perturb the regulation of apoptosis and proliferation in
lymphoid cells. It is interesting to note that the phenotype
of bcl-10 transgenic mice is similar to that of TRAF2-defi-
cient mice reported previously (Yeh et al., 1997) and
TRAF2 has been reported to interact with bcl-10 (Yoneda
et al., 2000). This suggests that bcl-10 may interfere with
TRAF2-dependent signaling pathways necessary for lym-
phocyte proliferation.
Bcl-10 has also been identified based on the presence
within its NH2 terminus of a predicted CARD motif (Hof-
mann et al., 1997; Koseki et al., 1999; Srinivasula et al.,
1999; Thome et al., 1999; Yan et al., 1999), which suggests
an involvement of the bcl-10 protein in CARD-dependent
signaling pathways commonly associated with the regula-
tion of apoptotic or inflammatory processes. In overex-
pression studies, bcl-10 has been reported to induce apop-
tosis and activation of NF-kB (Costanzo et al., 1999;
Koseki et al., 1999; Srinivasula et al., 1999; Willis et al.,
1999; Yan et al., 1999; Zhang et al., 1999). However, rela-
tive to its viral counterpart, activation of NF-kB by bcl-10
is very weak (Srinivasula et al., 1999; Thome et al., 1999),
suggesting distinct roles of v-E10 and bcl-10 in the regula-
tion of NF-kB. Consistently, whereas wild-type bcl-10 was
found to suppress transformation of rat embryonic fibro-
blasts by ras and cooperating oncogenes, v-E10 was found
to enhance this process (Willis et al., 1999), further sup-
porting the idea that v-E10 and bcl-10 may exert antago-
nistic functions in vivo.
Expression of v-E10 has been shown to activate both the
JNK and the NF-kB transcriptional pathways (Koseki et
al., 1999; Srinivasula et al., 1999; Thome et al., 1999; Willis
et al., 1999), most likely through interaction with specific
members of the TRAF family (Thome et al., 1999). We
found that JNK activation by the viral protein was inde-
pendent of its membrane localization or intactness of its
CARD (data not shown), but required an intact TRAF6-
binding site. In contrast, mutation of the COOH-terminal
membrane-targeting Cys–Cys motif of v-E10 partially im-
paired the activation of NF-kB and mutation of the
CARD motif completely abolished NF-kB activation.
Therefore, bcl-10 may represent a natural inhibitory regu-
lator of the NF-kB activation pathway and its inhibitory
function would be overcome by its phosphorylation and
interaction with v-E10 at the plasma membrane (or poten-
tially by its aggregation in overexpression studies). This
hypothesis is supported by (a) the observation that NF-kB
activation by v-E10 involves both membrane localization
and a functional v-E10–CARD, (b) v-E10–induced NF-kB
activation is inhibited by a dominant negative version of
the bcl-10 binding protein TRAF1, and (c) the phenotype
of the bcl-10 transgenic mouse (see above).
It is interesting to compare v-E10 with the EBV protein,
LMP1. LMP1 is a protein with six transmembrane-span-
ning domains that contributes to EBV-induced transfor-
mation of B lymphocytes (Damania et al., 2000). LMP1
mimics the function of the B lymphocyte activation anti-
gen CD40 by recruiting TRAFs to the membrane, thereby
activating the NF-kB pathway. Similarly, v-E10 may
mimic the function of an unknown receptor or membrane-
associated protein that recruits bcl-10 and hence TRAFs
to the membrane. Like LMP1 that contributes to EBV-
induced transformation of B lymphocytes, v-E10 may thus
contribute to the cellular proliferation occurring in lym-
phocytes of EHV-2–infected horses.
Finally, our analysis of the v-E10 function also extends
our understanding of the reported phosphorylation of bcl-
10 (Koseki et al., 1999; Srinivasula et al., 1999; Thome et
al., 1999; Yoneda et al., 2000). Phosphorylation of bcl-10 at
the plasma membrane may be important for the regulation
of its physiological function. Most likely, relocalization of
bcl-10 to the membrane facilitates its phosphorylation by
an unknown membrane-proximal kinase in vivo. Alterna-
tively, phosphorylated bcl-10 may be continuously gener-
ated but rapidly turned over, and the interaction of bcl-10
with v-E10 (or its postulated functional homologue in un-
infected cells) at the plasma membrane may stabilize the
otherwise short-lived phosphorylated forms of bcl-10. Fur-
ther studies aimed at the identification and subsequent
mutation of the bcl-10 phosphorylation sites should help
to clarify this issue.
The authors would like to thank Jean-Luc Bodmer for help with statistics
and Kim Burns for careful reading of the manuscript.
This work was supported by a grant from the Swiss National Cancer
Ligue (to M. Thome and J. Tschopp), an M.D.-Ph.D. fellowship of the
Swiss Academy of Medical Sciences (to O. Gaide), and a postdoctoral fel-
lowship of the Association pour la Recherche sur le Cancer (to O.
Micheau). 
Submitted: 14 November 2000
Revised: 22 January 2001
Accepted: 23 January 2001
References
Apostolou, S., A. De Rienzo, S.S. Murthy, S.C. Jhanwar, and J.R. Testa. 1999.
Absence of BCL10 mutations in human malignant mesothelioma. Cell. 97:
684–686.
Arch, R.H., R.W. Gedrich, and C.B. Thompson. 1998. Tumor necrosis factor
receptor-associated factors (TRAFs)—a family of adapter proteins that reg-
ulates life and death. Genes Dev. 12:2821–2830.
Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A.
Smith, and K. Struhl. 1999. Introduction of DNA into mammalian cells. In
Current Protocols in Molecular Biology. John Wiley & Sons, Inc. New York.
Blakeslee, J.R., Jr., R.G. Olsen, E.S. McAllister, J. Fassbender, and R. Dennis.
1975. Evidence of respiratory tract infection induced by equine herpesvirus,
type 2, in the horse. Can. J. Microbiol. 21:1940–1946.
Bodmer, J.L., K. Burns, P. Schneider, K. Hofmann, V. Steiner, M. Thome, T.
Bornand, M. Hahne, M. Schroter, K. Becker, et al. 1997. TRAMP, a novel
apoptosis-mediating receptor with sequence homology to tumor necrosis
factor receptor 1 and Fas (Apo-1/CD95). Immunity. 6:79–88.
Bordier, C. 1981. Phase separation of integral membrane proteins in Triton
X-114 solution. J. Biol. Chem. 256:1604–1607.
Casey, P.J., and M.C. Seabra. 1996. Protein prenyltransferases. J. Biol. Chem.
271:5289–5292.
Costanzo, A., C. Guiet, and P. Vito. 1999. c-E10 is a caspase-recruiting domain-
containing protein that interacts with components of death receptors signal-
The Journal of Cell Biology, Volume 152, 2001 1122
ing pathway and activates nuclear factor-kappaB. J. Biol. Chem. 274:20127–
20132.
Damania, B., J.K. Choi, and J.U. Jung. 2000. Signaling activities of gammaher-
pesvirus membrane proteins. J. Virol. 74:1593–1601.
Fakruddin, J.M., R.S.K. Chaganti, and V.V.V.S. Murty. 1999. Lack of BCL10
mutations in germ cell tumors and B cell lymphomas. Cell. 97:683–684.
Farnsworth, C.C., M.C. Seabra, L.H. Ericsson, M.H. Gelb, and J.A. Glomset.
1994. Rab geranylgeranyl transferase catalyzes the geranylgeranylation of
adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A. Proc.
Natl. Acad. Sci. USA. 91:11963–11967.
Francis, M.J., G.Z. Hastings, F. Brown, J. McDermed, Y.A. Lu, and J.P. Tam.
1991. Immunological evaluation of the multiple antigen peptide (MAP) sys-
tem using the major immunogenic site of foot-and-mouth disease virus. Im-
munology. 73:249–254.
Glomset, J.A., and C.C. Farnsworth. 1994. Role of protein modification reac-
tions in programming interactions between ras-related GTPases and cell
membranes. Annu. Rev. Cell Biol. 10:181–205.
Guiet, C., and P. Vito. 2000. Caspase recruitment domain (CARD)-dependent
cytoplasmic filaments mediate bcl10-induced NF-kB activation. J. Cell Biol.
148:1131–1140.
Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Long-
necker, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by
Epstein-Barr virus latent membrane protein 1 protects infected B cells from
programmed cell death. Cell. 65:1107–1115.
Hofmann, K., P. Bucher, and J. Tschopp. 1997. The CARD domain: a new ap-
optotic signalling motif. Trends Biochem. Sci. 22:155–156.
Irmler, M., V. Steiner, C. Ruegg, H. Wajant, and J. Tschopp. 2000. Caspase-
induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-medi-
ated apoptosis. FEBS Lett. 468:129–133.
Koseki, T., N. Inohara, S. Chen, R. Carrio, J. Merino, M.O. Hottiger, G.J. Na-
bel, and G. Nunez. 1999. CIPER, a novel NF kappaB-activating protein con-
taining a caspase recruitment domain with homology to Herpesvirus-2 pro-
tein E10. J. Biol. Chem. 274:9955–9961.
Laherty, C.D., H.M. Hu, A.W. Opipari, F. Wang, and V.M. Dixit. 1992. The
Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein ex-
pression by activating nuclear factor kappa B. J. Biol. Chem. 267:24157–
24160.
Lee, H., J.K. Choi, M. Li, K. Kaye, E. Kieff, and J.U. Jung. 1999. Role of cellu-
lar tumor necrosis factor receptor-associated factors in NF-kappaB activa-
tion and lymphocyte transformation by herpesvirus Saimiri STP. J. Virol. 73:
3913–3919.
Liu, L., P. Moesner, N.L. Kovach, R. Bailey, A.D. Hamilton, S.M. Sebti, and
J.M. Harlan. 1999. Integrin-dependent leukocyte adhesion involves geran-
ylgeranylated protein(s). J. Biol. Chem. 274:33334–33340.
Opipari, A.W., Jr., H.M. Hu, R. Yabkowitz, and V.M. Dixit. 1992. The A20 zinc
finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol.
Chem. 267:12424–12427.
Peter, M., P. Chavrier, E.A. Nigg, and M. Zerial. 1992. Isoprenylation of rab
proteins on structurally distinct cysteine motifs. J. Cell Sci. 102:857–865.
Resh, M.D. 1999. Fatty acylation of proteins: new insights into membrane tar-
geting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta.
1451:1–16.
Seabra, M.C., J.L. Goldstein, T.C. Sudhof, and M.S. Brown. 1992. Rab ge-
ranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-bind-
ing proteins terminating in Cys-X-Cys or Cys-Cys. J. Biol. Chem. 267:14497–
14503.
Srinivasula, S.M., M. Ahmad, J.H. Lin, J.L. Poyet, T. Fernandes-Alnemri, P.N.
Tsichlis, and E.S. Alnemri. 1999. CLAP, a novel caspase recruitment do-
main-containing protein in the tumor necrosis factor receptor pathway, reg-
ulates NF-kappaB activation and apoptosis. J. Biol. Chem. 274:17946–17954.
Telford, E.A., M.S. Watson, H.C. Aird, J. Perry, and A.J. Davison. 1995. The
DNA sequence of equine herpesvirus 2. J. Mol. Biol. 249:520–528.
Thome, M., F. Martinon, K. Hofmann, V. Rubio, V. Steiner, P. Schneider, C.
Mattmann, and J. Tschopp. 1999. Equine herpesvirus-2 E10 gene product,
but not its cellular homologue, activates NF-kappaB transcription factor and
c-Jun N-terminal kinase. J. Biol. Chem. 274:9962–9968.
Tschopp, J., M. Irmler, and M. Thome. 1998. Inhibition of fas death signals by
FLIPs. Curr. Opin. Immunol. 10:552–558.
Wei, C., R. Lutz, M. Sinensky, and I.G. Macara. 1992. p23rab2, a ras-like GTP-
ase with a -GGGCC C-terminus, is isoprenylated but not detectably car-
boxymethylated in NIH3T3 cells. Oncogene. 7:467–473.
Willis, T.G., D.M. Jadayel, M.Q. Du, H. Peng, A.R. Perry, M. Abdul-Rauf, H.
Price, L. Karran, O. Majekodunmi, I. Wlodarska, et al. 1999. Bcl10 is in-
volved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multi-
ple tumor types. Cell. 96:35–45.
Yan, M., J. Lee, S. Schilbach, A. Goddard, and V. Dixit. 1999. mE10, a novel
caspase recruitment domain-containing proapoptotic molecule. J. Biol.
Chem. 274:10287–10292.
Yeh, W.C., A. Shahinian, D. Speiser, J. Kraunus, F. Billia, A. Wakeham, J.L. de
la Pompa, D. Ferrick, B. Hum, N. Iscove, et al. 1997. Early lethality, func-
tional NF-kappaB activation, and increased sensitivity to TNF-induced cell
death in TRAF2-deficient mice. Immunity. 7:715–725.
Yoneda, T., K. Imaizumi, M. Maeda, D. Yui, T. Manabe, T. Katayama, N. Sato,
F. Gomi, T. Morihara, Y. Mori, et al. 2000. Regulatory mechanisms of
TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associ-
ated protein. J. Biol. Chem. 275:11114–11120.
Zhang, Q., R. Siebert, M. Yan, B. Hinzmann, X. Cui, L. Xue, K.M. Rakestraw,
C.W. Naeve, G. Beckmann, D.D. Weisenburger, et al. 1999. Inactivating mu-
tations and overexpression of BCL10, a caspase recruitment domain-contain-
ing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat. Genet. 22:63–68.
